Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

Luis E. Simental‐Mendía; Adriana Sánchez‐García; Enrique Linden‐Torres; Mario Simental‐Mendía

doi:10.1111/bcp.14855

journal article Apr 29, 2021

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

Luis E. Simental‐Mendía

Adriana Sánchez‐García Enrique Linden‐Torres Mario Simental‐Mendía

British Journal of Clinical Pharmacology Vol. 87 No. 11 pp. 4140-4149 · Wiley

View at Publisher Save 10.1111/bcp.14855

Abstract

AimsPrevious studies have reported an elevation in adiponectin concentrations using glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) therapy; however, this possible pleiotropic effect is still uncertain. Thus, the objective of this meta‐analysis of randomized controlled trials was to assess the impact of GLP‐1 RA on adiponectin levels.MethodsThis systematic review and meta‐analysis included randomized controlled trials investigating the effect of GLP‐1 RA on circulating adiponectin concentrations. Studies from PubMed, Web of Science, Scopus, and Google Scholar databases were included. A random‐effects model and a sensitivity analysis using the leave 1‐out method were conducted.ResultsA meta‐analysis of 20 randomized controlled trials involving 1497 individuals demonstrated a significant increase in adiponectin levels after GLP‐1 RA administration (weighted mean difference [WMD]: 0.59 μg/mL, 95% confidence interval [CI]: 0.10, 1.08, P = .02). Particularly, liraglutide had a significant effect on adiponectin (WMD: 0.55 μg/mL, 95% CI: 0.04, 1.06, P = .04), while exenatide did not affect these concentrations (WMD: 0.60 μg/mL, 95% CI: −0.23, 1.42, P = .16).ConclusionGLP‐1 RA treatment is associated with an increase in adiponectin levels.

Topics

No keywords indexed for this article. Browse by subject →

References

43

[1]

10.5114/aoms.2013.33181

[2]

10.3390/ijms18061321

[3]

10.1038/oby.2002.150

[4]

10.2337/dc14-2775

[5]

10.1155/2014/658913

[6]

10.1371/journal.pone.0169469

[7]

10.1016/j.bbrc.2009.10.015

[8]

10.1111/j.1464-5491.2012.03699.x

[9]

10.2337/dc09-2361

[10]

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

D. Moher, A. Liberati, J. Tetzlaff et al.

BMJ 10.1136/bmj.b2535

[11]

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al.

BMJ 10.1136/bmj.d5928

[12]

Estimating the mean and variance from the median, range, and the size of a sample

Stela Pudar Hozo, Benjamin Djulbegovic, Iztok Hozo

BMC Medical Research Methodology 10.1186/1471-2288-5-13

[13]

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Xiang Wan, Wenqian Wang, Jiming Liu et al.

BMC Medical Research Methodology 10.1186/1471-2288-14-135

[14]

10.1111/bph.14748

[15]

10.1111/bph.14752

[16]

10.1016/j.diabres.2014.09.046

[17]

10.1016/j.diabres.2015.05.051

[18]

10.1016/j.diabres.2013.04.005

[19]

10.3892/etm.2017.4863

[20]

10.1038/oby.2011.152

[21]

10.1016/j.diabres.2015.12.003

[22]

10.1016/j.orcp.2017.01.003

[23]

10.1111/jdi.12269

[24]

10.1002/hep.30320

[25]

10.2337/dc12-0940

[26]

10.1002/osp4.324

[27]

10.1016/j.jhep.2015.08.038

[28]

10.1007/s00592-014-0638-3

[29]

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

A. Dutour, I. Abdesselam, P. Ancel et al.

Diabetes, Obesity and Metabolism 10.1111/dom.12680

[30]

10.1210/jc.2008-0115

[31]

10.1590/s0004-27302013000900005

[32]

10.1111/dom.13053

[33]

Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26‐week randomized controlled trial; mechanisms of weight loss

Husam Ghanim, Manav Batra, Kelly Green et al.

Diabetes, Obesity and Metabolism 10.1111/dom.14090

[34]

10.1016/j.cyto.2011.09.029

[35]

10.1007/s00421-010-1362-5

[36]

10.2337/dc08-1797

[37]

10.17235/reed.2020.6392/2019

[38]

10.1055/s-0035-1549878

[39]

10.1055/s-0042-121605

[40]

10.1055/s-0035-1569287

[41]

10.1055/a-0958-2441

[42]

10.1186/s12944-016-0372-7

[43]

10.3390/ijms20051190

Cited By

42

Glucagon-like peptide-1 receptor agonists and muscle mass effects

Alexandr Ceasovschih, Andreea Asaftei · 2025

Pharmacological Research

Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs

Richard Le, Mau T. Nguyen · 2024

Journal of Clinical Medicine

Metrics

42

Citations

43

References

Details

Published: Apr 29, 2021
Vol/Issue: 87(11)
Pages: 4140-4149
License: View

Authors

L

Luis E. Simental‐Mendía

Unidad de Investigación Biomédica, Delegación Durango, Instituto Mexicano del Seguro Social Mexico

A

Adriana Sánchez‐García

Universidad Autonoma de Nuevo Leon, Endocrinology Division University Hospital “Dr. José E. González”, School of Medicine Monterrey NL Mexico

E

Enrique Linden‐Torres

Unidad de Investigación Biomédica, Delegación Durango, Instituto Mexicano del Seguro Social Mexico

M

Mario Simental‐Mendía

Universidad Autonoma de Nuevo Leon, Department of Orthopedics and Traumatology University Hospital “Dr. José E. González”, School of Medicine Monterrey NL Mexico

Cite This Article

Luis E. Simental‐Mendía, Adriana Sánchez‐García, Enrique Linden‐Torres, et al. (2021). Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 87(11), 4140-4149. https://doi.org/10.1111/bcp.14855

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

You May Also Like